Background/Aim: Continuous venovenous hemofiltration with high-permeability hemofilters is a novel approach in the adjuvant therapy of septic patients. High-permeability hemofilters are characterized by an increased pore size which facilitates the filtration of inflammatory mediators. The present study examines whether intermittent high-permeability hemofiltration has an immunomodulatory effect on polymorphonuclear leukocytes and mononuclear cells. Methods: Twenty-eight septic patients with acute renal failure were randomly allocated to either receive intermittent high-permeability or conventional hemofiltration. Intermittent high-permeability hemofiltration consisted of a daily 12-hour course of high-permeability hemofiltration alternated by conventional hemofiltration. For high-permeability hemofiltration, a newly developed high-flux polyamide membrane (P2SH) with a nominal cutoff point of 60 kD was used. For conventional hemofiltration a high-flux polyamide hemofilter (Polyflux 11S, cutoff point 30 kD) was used. Results: The polymorphonuclear leukocyte phagocytosis activity before starting hemofiltration was almost double the rate of healthy controls in both groups (p < 0.001). The phagocytosis rate decreased significantly during the course of intermittent high-permeability hemofiltration (p < 0.05), whereas the values remained unchanged in the conventional hemofiltration group. Incubation of high-permeability filtrates with blood from healthy donors resulted in a significant induction of phagocytosis (p < 0.001), whereas conventional filtrates had no phagocytosis-stimulating effects. In addition, incubation of healthy-donor mononuclear cells with high-permeability but not conventional filtrates resulted in a significant tumor necrosis factor alpha release (p < 0.001). Conclusions: Intermittent high-permeability hemofiltration is a novel extracorporeal elimination modality which exhibits immunomodulatory effects on leukocytes, attenuating polymorphonuclear neutrophil phagocytosis. Further studies are necessary to elucidate whether these effects translate in a clinical improvement in patients suffering from sepsis.

Keywords:
High-permeability hemofiltration, Septic multiorgan failure, Mediator elimination, Leukocyte phagocytosis
1.
Morgera S, Kraft AK, Siebert G, Luft FC, Neumayer HH: Long-term outcomes in acute renal failure patients treated with continuous renal replacement therapies. Am J Kidney Dis 2002;40:275–279.
2.
Bone RC: Inhibitors of complement and neutrophils: A critical evaluation of their role in the treatment of sepsis. Crit Care Med 1992;20:891–898.
3.
Mallick AA, Ishizaka A, Stephens KE, Hatherill JR, Tazelaar HD, Raffin TA: Multiple organ damage caused by tumor necrosis factor and prevented by prior neutrophil depletion. Chest 1989;95:1114–1120.
4.
Carey PD, Byrne K, Jenkins JK, Sielaff TD, Walsh CJ, Fowler AA 3rd, Sugerman HJ: Ibuprofen attenuates hypochlorous acid production from neutrophils in porcine acute lung injury. J Surg Res 1990;49:262–270.
5.
Windsor AC, Walsh CJ, Mullen PG, Cook DJ, Fisher BJ, Blocher CR, Leeper-Woodford SK, Sugerman HJ, Fowler AA 3rd: Tumor necrosis factor-alpha blockade prevents neutrophil CD18 receptor upregulation and attenuates acute lung injury in porcine sepsis without inhibition of neutrophil oxygen radical generation. J Clin Invest 1993;91:1459–1468.
6.
Bloomfield GL, Ridings PC, Blocher CR, Fisher BJ, Sugerman HJ, Nagamoto H, Fowler AA: OPC-6535, a superoxide anion production inhibitor, attenuates acute lung injury. J Surg Res 1997;72:70–77.
7.
Heyderman RS, Ison CA, Peakman M, Levin M, Klein NJ: Neutrophil response to Neisseria meningitidis: Inhibition of adhesion molecule expression and phagocytosis by recombinant bactericidal/permeability-increasing protein (rBPI21). J Infect Dis 1999;179:1288–1292.
8.
Hewett JA, Schultze AE, VanCise S, Roth RA: Neutrophil depletion protects against liver injury from bacterial endotoxin. Lab Invest 1992;66:347–361.
9.
Heering P, Morgera S, Schmitz FJ, Schmitz G, Willers R, Schultheiss HP, Strauer BE, Grabensee B: Cytokine removal and cardiovascular hemodynamics in septic patients with continuous venovenous hemofiltration. Intensive Care Med 1997;23:288–296.
10.
Lee PA, Weger GW, Pryor RW, Matson JR: Effects of filter pore size on efficacy of continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1998;26:730–737.
11.
Morgera S, Buder HW, Lehmann C, Ziemer S, Haase M, Rocktäschel J, Beck W, Buck R, Göhl H, Kox WJ, Neumayer HH: High cut-off membrane haemofiltration in septic patients with multiorgan failure (abstract). J Am Soc Nephrol 2000;11:1705.
12.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJl: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. Chest 1992;101:1644–1655.
13.
Westlin WF, Gimbrone MA Jr: Neutrophil-mediated damage to human vascular endothelium: Role of cytokine activation. Am J Pathol 1993;142:117–128.
14.
Gossage JR, Kuratomi Y, Davidson JM, Lefferts PL, Snapper JR: Neutrophil elastase inhibitors, SC-37698 and SC-39026, reduce endotoxin-induced lung dysfunction in awake sheep. Am Rev Respir Dis 1993;147:1371–1379.
15.
Mallick AA, Ishizaka A, Stephens KE, Hatherill JR, Tazelaar HD, Raffin TA: Multiple organ damage caused by tumor necrosis factor and prevented by prior neutrophil depletion. Chest 1989;95:1114–1120.
16.
Simms HH, Frank MM, Quinn TC, Holland S, Gaither TA: Studies on phagocytosis in patients with acute bacterial infections. J Clin Invest 1989;83:252–260.
17.
Kaslovsky RA, Lai L, Parker K, Malik AB: Mediation of endothelial injury following neutrophil adherence to extracellular matrix. Am J Physiol 1993;264(4 Pt 1):L401–L405.
18.
Kaslovsky RA, Horgan MJ, Lum H, McCandless BK, Gilboa N, Wright SD, Malik AB: Pulmonary edema induced by phagocytosing neutrophils: Protective effect of monoclonal antibody against phagocyte CD18 integrin. Circ Res 1990;67:795–802.
19.
Bellomo R: Continuous hemofiltration as blood purification in sepsis. New Horiz 1995;3:732–737.
20.
Koperna T, Vogl S, Pöschl GP, Hamilton G, Roder G, Germann P: Cytokine pattern in patients who undergo hemofiltration for treatment of multiple organ failure. World J Surg 1998;22:2443–2448.
21.
Sieberth HG, Kierdorf HP: Is cytokine removal by continuous hemofiltration feasible? Kidney Int Suppl 1999;72:79–83.
22.
Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J: Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL-6 and TNF alpha plasma concentrations. Intensive Care Med 1997;23:878–884.
23.
Uchino S, Bellomo R, Goldsmith D, Davenport P, Cole L, Baldwin I, Panagiotopoulos S, Tipping P: Super high flux hemofiltration: A new technique for cytokine removal. Intensive Care Med 2002;28:651–655.
24.
Billiau A, Vandekerckhove F: Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest 1991;21:559–573.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.